Education
About Us
Working with TipRanks
Follow Us
Glenmark Life Sciences Limited (IN:GLS)
:GLS
GLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range₹821.00 - ₹1,335.00
Previous CloseN/A
Volume27.91K
Average Volume (3M)4.96K
Market Cap
₹124.09B
Enterprise Value₹45.50B
Total Cash (Recent Filing)₹3.02B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)25.3
Beta0.69
Next Earnings
Aug 08, 2025EPS Estimate
10.8Last Dividend Ex-Date
Oct 17, 2023Dividend Yield3.96%
Share Statistics
EPS (TTM)11.35
Shares Outstanding122,629,150
10 Day Avg. Volume5,563
30 Day Avg. Volume4,955
Financial Highlights & Ratios
PEG Ratio1.48
Price to Book (P/B)2.25
Price to Sales (P/S)0.00
P/FCF Ratio33.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
GLS FAQ
What was Glenmark Life Sciences Limited’s price range in the past 12 months?
Glenmark Life Sciences Limited lowest stock price was ₹821.00 and its highest was ₹1335.00 in the past 12 months.
What is Glenmark Life Sciences Limited’s market cap?
Glenmark Life Sciences Limited’s market cap is ₹124.09B.
When is Glenmark Life Sciences Limited’s upcoming earnings report date?
Glenmark Life Sciences Limited’s upcoming earnings report date is Aug 08, 2025 which is in 28 days.
How were Glenmark Life Sciences Limited’s earnings last quarter?
Glenmark Life Sciences Limited released its earnings results on May 15, 2025. The company reported ₹11.35 earnings per share for the quarter, beating the consensus estimate of ₹10.2 by ₹1.15.
Is Glenmark Life Sciences Limited overvalued?
According to Wall Street analysts Glenmark Life Sciences Limited’s price is currently Overvalued.
Does Glenmark Life Sciences Limited pay dividends?
Glenmark Life Sciences Limited pays a Semiannually dividend of ₹22.5 which represents an annual dividend yield of 3.96%. See more information on Glenmark Life Sciences Limited dividends here
What is Glenmark Life Sciences Limited’s EPS estimate?
Glenmark Life Sciences Limited’s EPS estimate is 10.8.
How many shares outstanding does Glenmark Life Sciences Limited have?
Glenmark Life Sciences Limited has 122,629,150 shares outstanding.
What happened to Glenmark Life Sciences Limited’s price movement after its last earnings report?
Glenmark Life Sciences Limited reported an EPS of ₹11.35 in its last earnings report, beating expectations of ₹10.2. Following the earnings report the stock price went up 2.168%.
Which hedge fund is a major shareholder of Glenmark Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:GLS
Company Description
Glenmark Life Sciences Limited
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.
Technical Analysis
Caplin Point Laboratories Limited
―
Granules India Limited
―
Marksans Pharma Limited
―
Sanofi India Limited
―
Shilpa Medicare Limited
―